行情

PTN

PTN

Palatin科技
AMEX

实时行情|Nasdaq Last Sale

0.5900
-0.0200
-3.28%
交易中 10:10 06/15 EDT
开盘
0.6100
昨收
0.6100
最高
0.6120
最低
0.5900
成交量
44.57万
成交额
--
52周最高
1.300
52周最低
0.3750
市值
1.36亿
市盈率(TTM)
-5.1709
分时
5日
1月
3月
1年
5年
BRIEF-Palatin Announces Adjournment Of Annual Meeting Of Stockholders
reuters.com · 5天前
资本使用回报率概述：Palatin Technologies
During Q3, Palatin Technologies (AMEX:PTN) brought in sales totaling $88.74 thousand. However, earnings decreased 29.88%, resulting in a loss of $6.49 million. In Q2, Palatin Technologies brought in $-163.97 thousand in sales but lost $9.25 million in earn...
Benzinga · 05/17 17:33
Brief-Palatin报告第三季度每股亏损0.02美元
reuters.com · 05/17 11:57
Palatin Technologies Q3每股收益（$ 0.02）超出$（0.04）估计，销售额$ 88.74K错过$ 128万估计
Palatin Technologies (AMEX:PTN) reported quarterly losses of $(0.02) per share which beat the analyst consensus estimate of $(0.04) by 50 percent. This is unchanged from the same period last year. The company reported
Benzinga · 05/17 11:40
预计2021年5月17日的收入
  Companies Reporting Before The Bell • Hycroft Mining Holding (NASDAQ:HYMC) is estimated to report earnings for its first quarter.
Benzinga · 05/17 08:10
-Earnings Flash（PTN）拉丁科技公布第三季度亏损-0.02美元，而Street Est亏损-0.04美元
MT Newswires · 05/17 07:46
每日生物技术脉动：默克公司的Keytruda获得美国食品和药物管理局（FDA）的另一项批准，Moderna减免了收入损失，Chemocentryx Adcom
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 5)
Benzinga · 05/06 11:49
Brief-Palatin宣布Vyleesi®（布雷莫来肽注射液）的美国专利期限延长
reuters.com · 05/04 11:32
更多
财务预测
实际值（美元）
预测值（美元）
利润表更多
净利润（美元）
同比（%）
资产负债表更多
总资产（美元）
总负债（美元）
资产负债率（%）
现金流表更多
经营现金流（美元）
同比（%）
了解PTN最新的财务预测，通过PTN每股收益，每股净资产，每股现金流等数据分析Palatin科技近期的经营情况，然后做出明智的投资选择。
分析师评级

3位分析师的综合评级

强力推荐

免责声明：分析师观点仅供投资者决策参考，不构成任何买卖投资建议。

目标价格预测
分析师预测PTN价格均价为2.333，最高价位3.000，最低价为2.000。
EPS
机构持股
总机构数: 98
机构持股: 4,469.12万
持股比例: 19.43%
总股本: 2.30亿
类型机构数股数
增持
32
480.92万
建仓
20
135.83万
减持
17
134.26万
平仓
6
112.48万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-0.81%
制药与医学研究
-0.47%
高管信息
Chairman/Independent Director
John Prendergast
President/Chief Executive Officer/Director
Carl Spana
Chief Financial Officer/Chief Operating Officer/Executive Vice President/Treasurer/Secretary
Stephen Wills
Chief Financial Officer/Chief Operating Officer/Executive Vice President/Treasurer/Secretary
stephen Wills
Independent Director
Robert deVeer
Independent Director
Alan Dunton
Independent Director
Joseph Hull
Independent Director
Anthony Manning
Independent Director
Arlene Morris
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
更多
PTN 简况
Palatin Technologies, Inc. (Palatin) is a biopharmaceutical company. The Company is engaged in developing medicines based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. The Company’s product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with unmet medical need and commercial potential. The melanocortin receptor (MCr) system is hormone driven, with effects on food intake, metabolism, sexual function, inflammation and immune system responses. There are five melanocortin receptors, MC1r through MC5r. The natriuretic peptide receptor (NPR) system regulates cardiovascular functions, and therapeutic agents modulating this system have potential to treat fibrotic diseases, cardiovascular diseases, including reducing cardiac hypertrophy and fibrosis, heart failure, acute asthma, pulmonary diseases and hypertension.

微牛提供Palatin Technologies, Inc.(AMEX-PTN)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的PTN股票新闻，以帮助您做出投资决策。

模拟交易：模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易PTN股票基本功能。